Phase 4 N=1,179 Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI
Acute Upper Respiratory Track Infection
Primary: Antibiotic Sparing — 89; 121 Participants — p=0.025
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases
Peripheral Arterial Disease
Primary: Overall Image Quality of MRA Images — 56; 48 Images
Phase 4 N=101 To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Heartburn
Primary: Change in the Frequency of Heartburn During the 7-day Period Prior to the 8 Week Visit (Visit 3) Compared to the Frequency of Heartburn During the 7-day Period Prior to…
Phase 4 N=1,143 Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
Hypertension
Primary: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8 — -15.3; -11.5 mmHg
Phase 4 N=2,591 Trial Comparing Different Methods of Support With Stopping Smoking (PORTSSS/Stop Together Trial)
Tobacco Smoking
Primary: Self-reported, Prolonged Abstinence From Smoking Between a Quit Date and 6 Months Afterwards. — 127; 124; 114; 104 participants
Phase 4 N=17 Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Major Depressive Disorder
Primary: Stockings of Cambridge (SOC) Mean Initial Thinking Time for 3-move Problems — -4485.50 milliseconds
Phase 4 N=95 Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
Schizophrenia · Psychotic Disorders · Substance Abuse
Primary: Change Over Time in Frequency of Heavy Drinking Days (Used to Evaluate Treatment Efficacy) — -.11; .68 heavy drinking days per week — p=0.054
Phase 4 N=222 Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo
Healthy
Primary: Percentage of Participants With a 50 Percent (%) or More Reduction in Sperm Concentration From Baseline (Bsl) to End of Study (EOS) — 9.2; 3.2 percentage of participants
Phase 4 N=50 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
Pancreatic Cancer · Bile Duct Cancer
Primary: Postoperative Infectious Complication — 7; 15 participants — p=<0.05
Phase 4 N=34 Different Safety Profile of Risperidone and Paliperidone Extended-release
Schizophrenia
Primary: Assessment of Negative Symptoms and Neuroleptic Induced Deficit Syndromes by Objective Rating Scales — -1.30; -0.28; -0.66; -0.70 units on a scale
Phase 4 N=15 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
Inflammatory Bowel Disease · Uterine Cervical Dysplasia
Primary: Twelve Month Antibody Response to the Human Papillomavirus (HPV) Vaccine (Geometric Mean Titers [GMT]) — 120.5; 175.0; 861.0; 68.9 mMU/mL
Phase 4 N=46 Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome
Metabolic Syndrome
Primary: Marker of Fibrinolysis — 10.5; 12.3 ng/mL
Phase 4 N=29 Vitamin D Repletion in Stone Formers With Hypercalciuria
Nephrolithiasis · Urolithiasis · Idiopathic Hypercalciuria
Primary: Change in 24 Hour Urine Calcium — 2 mg/day
Phase 4 N=48 A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
Acne Vulgaris
Primary: Erythema (Redness) — 0.66; 0.91; 0.55; 0.74 units on a scale
Phase 4 N=23 Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients
Hypertension · Chronic Kidney Disease
Primary: The Change of Blood Pressure — -22.7; -5 mmHg